T-Mobile Magenta Drive for BMW Powers America’s First 5G Connected Cars
Another first in 5G! Today, T-Mobile (NASDAQ: TMUS) introduced Magenta Drive for BMW and the first 5G connected cars in the U.S. Available now, the all-new 2022 BMW iX and i4 come T-Mobile 5G ready with unlimited 5G data to turn your car into a mobile Wi-Fi hotspot and connect all your in-car devices, and unlimited voice calling. As vehicles become even more connected to the world around them, people on the go can access America’s largest and fastest 5G network.
Available for $20 per month to postpaid customers, T-Mobile Magenta Drive for BMW can turn any qualified BMW vehicle into a Wi-Fi hotspot over America’s most awarded 5G network — to enable blazing fast data and Wi-Fi, as well as voice calls on T-Mobile's nationwide network:
- Leave your phone behind with in-car calling using your personal cell phone number.
- Never miss a call with simultaneous incoming call notifications between phone and vehicle.
- Download content on up to 10 devices at the same time with unlimited 5G hotspot data.
- Log-in to any compatible BMW and follow-me connectivity personalizes everything, just like in your own car.
Magenta Drive for BMW gives customers unlimited 5G hotspot data so passengers can go online to their heart’s content. Additionally, passengers will get a stronger, more stable cellular signal than before — as well as higher throughput for 5G in-car data and Wi-Fi — thanks to advanced antenna systems in the all-new BMW iX and i4.
“In 2019 we lit up the first nationwide 5G network, and today we mark another milestone that builds on our 5G leadership,” said Callie Field, President, T-Mobile Business Group. “In another 5G first, we’ve delivered America’s first 5G connected cars, and we’re honored to do it together with BMW, who entrust their vehicles’ connectivity to T-Mobile.”
With Magenta Drive for BMW, drivers and passengers will have dependable 5G connectivity on America’s highways. T-Mobile’s 5G network covers more than 96 percent of Interstate Highway miles across America — 16 percent more than the next network, according to data from network intelligence provider, Ookla®.
Already, T-Mobile’s 5G network is changing the way people get things done. Nearly half the traffic on T-Mobile’s network is 5G, powering everything from cloud-based services and work from anywhere — to console-quality gaming and HD movie downloads. Truth…T-Mobile 5G has awakened fresh possibilities! And while 5G delivers speeds that let you work, video chat, game and more – millions of people are ditching their dreaded ISP for breakthrough 5G Home Internet. In fact, T-Mobile launched 5G Home Internet last April and just last quarter, the Un-carrier was America’s fastest growing broadband provider. Today, that growing list of 5G possibilities extends to the car as it becomes a more critical extension of home and work.
T-Mobile is America’s 5G leader with the largest and fastest 5G network. T-Mobile’s Extended Range 5G covers 310 million people across 1.8 million square miles. The Un-carrier is widening its lead with Ultra Capacity covering 210 million of those people — bringing super-fast 5G speeds to more places than anyone else.
For more information about Magenta Drive for BMW, and how to sign up, visit https://www.t-mobile.com/offers/bmw-car-wifi-plan.
Follow T-Mobile’s Official Twitter Newsroom @TMobileNews to stay up to date with the latest company news.
During congestion, heavy data users (>50GB/mo. for most plans) and customers choosing lower-prioritized plans may notice lower speeds than other customers; see plan for details. Video typically streams on smartphone/tablet in SD quality. Most Awarded: The most individual awards for nationwide 5G metrics in public reports from independent industry experts. Interstate Miles: Based on analysis by T-Mobile of Ookla® CoverageRight™ from Q4 2021 and Speedtest Intelligence® 5G background scans in Q4 2021. Fastest based onmedian, overall combined 5G speeds according to analysis by Ookla® of Speedtest Intelligence® data 5G download speeds for Q4 2021. Ookla trademarks used under license and reprinted with permission.
About T-Mobile
T-Mobile U.S. Inc. (NASDAQ: TMUS) is America’s supercharged Un-carrier, delivering an advanced 4G LTE and transformative nationwide 5G network that will offer reliable connectivity for all. T-Mobile’s customers benefit from its unmatched combination of value and quality, unwavering obsession with offering them the best possible service experience and undisputable drive for disruption that creates competition and innovation in wireless and beyond. Based in Bellevue, Wash., T-Mobile provides services through its subsidiaries and operates its flagship brands, T-Mobile, Metro by T-Mobile, and Sprint. For more information please visit: https://www.t-mobile.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220316005678/en/
Contact information
Media Contact
T-Mobile US, Inc. Media Relations
MediaRelations@t-mobile.com
Investor Relations Contact
T-Mobile US, Inc.
investor.relations@t-mobile.com
https://investor.t-mobile.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom